Therapeutic potential of MEK inhibition in acute myelogenous leukemia: Rationale for "vertical" and "lateral" combination strategies

Maria Rosaria Ricciardi, Maria Cristina Scerpa, Paola Bergamo, Ludovica Ciuffreda, Maria Teresa Petrucci, Sabina Chiaretti, Simona Tavolaro, Maria Grazia Mascolo, Stephen L. Abrams, Linda S. Steelman, Twee Tsao, Antonio Marchetti, Marina Konopleva, Donatella Del Bufalo, Francesco Cognetti, Robin Foà, Michael Andreeff, James A. McCubrey, Agostino Tafuri, Michele Milella

Research output: Contribution to journalArticle

Abstract

In hematological malignancies, constitutive activation of the RAF/MEK/ERK pathway is frequently observed, conveys a poor prognosis, and constitutes a promising target for therapeutic intervention. Here, we investigated the molecular and functional effects of pharmacologicalMEK inhibition in cell line models of acute myeloid leukemia (AML) and freshly isolated primary AML samples. The small-molecule, ATP-non-competitive, MEK inhibitor PD0325901 markedly inhibited ERK phosphorylation and growth of several AML cell lines and approximately 70 % of primary AML samples. Growth inhibition was due to G1-phase arrest and induction of apoptosis. Transformation by constitutively active upstream pathway elements (HRAS, RAF-1, and MEK) rendered FDC-P1 cells exquisitely prone to PD0325901-induced apoptosis. Gene and protein expression profiling revealed a selective effect of PD0325901 on ERK phosphorylation and compensatory upregulation of the RAF/MEK and AKT/p70S6K kinase modules, potentially mediating resistance to drug-induced growth inhibition. Consequently, in appropriate cellular contexts, both "vertical" (i.e., inhibition of RAF and MEK along the MAPK pathway) and "lateral" (i.e., simultaneous inhibition of the MEK/ERK and mTOR pathways) combination strategies may result in synergistic anti-leukemic effects. Overall, MEK inhibition exerts potent growth inhibitory and proapoptotic activity in preclinical models of AML, particularly in combination with other pathway inhibitors. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML.

Original languageEnglish
Pages (from-to)1133-1144
Number of pages12
JournalJournal of Molecular Medicine
Volume90
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Acute Myeloid Leukemia
MAP Kinase Signaling System
Growth
Therapeutics
Phosphorylation
Apoptosis
70-kDa Ribosomal Protein S6 Kinases
Cell Line
G1 Phase
Gene Expression Profiling
Hematologic Neoplasms
Myeloid Cells
Drug Resistance
Phosphotransferases
Up-Regulation
Adenosine Triphosphate
PD 0325901
Proteins

Keywords

  • Combinations
  • Hematological malignancies
  • MAPK
  • Resistance
  • Sensitivity
  • Synergism

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Therapeutic potential of MEK inhibition in acute myelogenous leukemia : Rationale for "vertical" and "lateral" combination strategies. / Ricciardi, Maria Rosaria; Scerpa, Maria Cristina; Bergamo, Paola; Ciuffreda, Ludovica; Petrucci, Maria Teresa; Chiaretti, Sabina; Tavolaro, Simona; Mascolo, Maria Grazia; Abrams, Stephen L.; Steelman, Linda S.; Tsao, Twee; Marchetti, Antonio; Konopleva, Marina; Del Bufalo, Donatella; Cognetti, Francesco; Foà, Robin; Andreeff, Michael; McCubrey, James A.; Tafuri, Agostino; Milella, Michele.

In: Journal of Molecular Medicine, Vol. 90, No. 10, 10.2012, p. 1133-1144.

Research output: Contribution to journalArticle

Ricciardi, MR, Scerpa, MC, Bergamo, P, Ciuffreda, L, Petrucci, MT, Chiaretti, S, Tavolaro, S, Mascolo, MG, Abrams, SL, Steelman, LS, Tsao, T, Marchetti, A, Konopleva, M, Del Bufalo, D, Cognetti, F, Foà, R, Andreeff, M, McCubrey, JA, Tafuri, A & Milella, M 2012, 'Therapeutic potential of MEK inhibition in acute myelogenous leukemia: Rationale for "vertical" and "lateral" combination strategies', Journal of Molecular Medicine, vol. 90, no. 10, pp. 1133-1144. https://doi.org/10.1007/s00109-012-0886-z
Ricciardi, Maria Rosaria ; Scerpa, Maria Cristina ; Bergamo, Paola ; Ciuffreda, Ludovica ; Petrucci, Maria Teresa ; Chiaretti, Sabina ; Tavolaro, Simona ; Mascolo, Maria Grazia ; Abrams, Stephen L. ; Steelman, Linda S. ; Tsao, Twee ; Marchetti, Antonio ; Konopleva, Marina ; Del Bufalo, Donatella ; Cognetti, Francesco ; Foà, Robin ; Andreeff, Michael ; McCubrey, James A. ; Tafuri, Agostino ; Milella, Michele. / Therapeutic potential of MEK inhibition in acute myelogenous leukemia : Rationale for "vertical" and "lateral" combination strategies. In: Journal of Molecular Medicine. 2012 ; Vol. 90, No. 10. pp. 1133-1144.
@article{34493b2b4d1141e198e97fdaecfdd419,
title = "Therapeutic potential of MEK inhibition in acute myelogenous leukemia: Rationale for {"}vertical{"} and {"}lateral{"} combination strategies",
abstract = "In hematological malignancies, constitutive activation of the RAF/MEK/ERK pathway is frequently observed, conveys a poor prognosis, and constitutes a promising target for therapeutic intervention. Here, we investigated the molecular and functional effects of pharmacologicalMEK inhibition in cell line models of acute myeloid leukemia (AML) and freshly isolated primary AML samples. The small-molecule, ATP-non-competitive, MEK inhibitor PD0325901 markedly inhibited ERK phosphorylation and growth of several AML cell lines and approximately 70 {\%} of primary AML samples. Growth inhibition was due to G1-phase arrest and induction of apoptosis. Transformation by constitutively active upstream pathway elements (HRAS, RAF-1, and MEK) rendered FDC-P1 cells exquisitely prone to PD0325901-induced apoptosis. Gene and protein expression profiling revealed a selective effect of PD0325901 on ERK phosphorylation and compensatory upregulation of the RAF/MEK and AKT/p70S6K kinase modules, potentially mediating resistance to drug-induced growth inhibition. Consequently, in appropriate cellular contexts, both {"}vertical{"} (i.e., inhibition of RAF and MEK along the MAPK pathway) and {"}lateral{"} (i.e., simultaneous inhibition of the MEK/ERK and mTOR pathways) combination strategies may result in synergistic anti-leukemic effects. Overall, MEK inhibition exerts potent growth inhibitory and proapoptotic activity in preclinical models of AML, particularly in combination with other pathway inhibitors. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML.",
keywords = "Combinations, Hematological malignancies, MAPK, Resistance, Sensitivity, Synergism",
author = "Ricciardi, {Maria Rosaria} and Scerpa, {Maria Cristina} and Paola Bergamo and Ludovica Ciuffreda and Petrucci, {Maria Teresa} and Sabina Chiaretti and Simona Tavolaro and Mascolo, {Maria Grazia} and Abrams, {Stephen L.} and Steelman, {Linda S.} and Twee Tsao and Antonio Marchetti and Marina Konopleva and {Del Bufalo}, Donatella and Francesco Cognetti and Robin Fo{\`a} and Michael Andreeff and McCubrey, {James A.} and Agostino Tafuri and Michele Milella",
year = "2012",
month = "10",
doi = "10.1007/s00109-012-0886-z",
language = "English",
volume = "90",
pages = "1133--1144",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Therapeutic potential of MEK inhibition in acute myelogenous leukemia

T2 - Rationale for "vertical" and "lateral" combination strategies

AU - Ricciardi, Maria Rosaria

AU - Scerpa, Maria Cristina

AU - Bergamo, Paola

AU - Ciuffreda, Ludovica

AU - Petrucci, Maria Teresa

AU - Chiaretti, Sabina

AU - Tavolaro, Simona

AU - Mascolo, Maria Grazia

AU - Abrams, Stephen L.

AU - Steelman, Linda S.

AU - Tsao, Twee

AU - Marchetti, Antonio

AU - Konopleva, Marina

AU - Del Bufalo, Donatella

AU - Cognetti, Francesco

AU - Foà, Robin

AU - Andreeff, Michael

AU - McCubrey, James A.

AU - Tafuri, Agostino

AU - Milella, Michele

PY - 2012/10

Y1 - 2012/10

N2 - In hematological malignancies, constitutive activation of the RAF/MEK/ERK pathway is frequently observed, conveys a poor prognosis, and constitutes a promising target for therapeutic intervention. Here, we investigated the molecular and functional effects of pharmacologicalMEK inhibition in cell line models of acute myeloid leukemia (AML) and freshly isolated primary AML samples. The small-molecule, ATP-non-competitive, MEK inhibitor PD0325901 markedly inhibited ERK phosphorylation and growth of several AML cell lines and approximately 70 % of primary AML samples. Growth inhibition was due to G1-phase arrest and induction of apoptosis. Transformation by constitutively active upstream pathway elements (HRAS, RAF-1, and MEK) rendered FDC-P1 cells exquisitely prone to PD0325901-induced apoptosis. Gene and protein expression profiling revealed a selective effect of PD0325901 on ERK phosphorylation and compensatory upregulation of the RAF/MEK and AKT/p70S6K kinase modules, potentially mediating resistance to drug-induced growth inhibition. Consequently, in appropriate cellular contexts, both "vertical" (i.e., inhibition of RAF and MEK along the MAPK pathway) and "lateral" (i.e., simultaneous inhibition of the MEK/ERK and mTOR pathways) combination strategies may result in synergistic anti-leukemic effects. Overall, MEK inhibition exerts potent growth inhibitory and proapoptotic activity in preclinical models of AML, particularly in combination with other pathway inhibitors. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML.

AB - In hematological malignancies, constitutive activation of the RAF/MEK/ERK pathway is frequently observed, conveys a poor prognosis, and constitutes a promising target for therapeutic intervention. Here, we investigated the molecular and functional effects of pharmacologicalMEK inhibition in cell line models of acute myeloid leukemia (AML) and freshly isolated primary AML samples. The small-molecule, ATP-non-competitive, MEK inhibitor PD0325901 markedly inhibited ERK phosphorylation and growth of several AML cell lines and approximately 70 % of primary AML samples. Growth inhibition was due to G1-phase arrest and induction of apoptosis. Transformation by constitutively active upstream pathway elements (HRAS, RAF-1, and MEK) rendered FDC-P1 cells exquisitely prone to PD0325901-induced apoptosis. Gene and protein expression profiling revealed a selective effect of PD0325901 on ERK phosphorylation and compensatory upregulation of the RAF/MEK and AKT/p70S6K kinase modules, potentially mediating resistance to drug-induced growth inhibition. Consequently, in appropriate cellular contexts, both "vertical" (i.e., inhibition of RAF and MEK along the MAPK pathway) and "lateral" (i.e., simultaneous inhibition of the MEK/ERK and mTOR pathways) combination strategies may result in synergistic anti-leukemic effects. Overall, MEK inhibition exerts potent growth inhibitory and proapoptotic activity in preclinical models of AML, particularly in combination with other pathway inhibitors. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML.

KW - Combinations

KW - Hematological malignancies

KW - MAPK

KW - Resistance

KW - Sensitivity

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=84867328500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867328500&partnerID=8YFLogxK

U2 - 10.1007/s00109-012-0886-z

DO - 10.1007/s00109-012-0886-z

M3 - Article

C2 - 22399013

AN - SCOPUS:84867328500

VL - 90

SP - 1133

EP - 1144

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 10

ER -